China Approves First Oral GLP-1 Weight-Loss Drug
Summary
China has approved its first oral GLP-1 weight-loss drug, Orforglipron, sold under the brand name Muyuda by Eli Lilly. The once-daily medicine is approved for adults with obesity or overweight and at least one related health condition.
Key Points
- China's National Medical Products Administration has approved the first oral GLP-1 weight-loss drug for sale in the country.
- The drug, Orforglipron, is produced by Eli Lilly and will be marketed under the brand Muyuda.
- It is approved for adults with obesity or overweight who have at least one related health problem.
- GLP-1 medicines are increasingly competing as oral alternatives to injectable weight-loss drugs.
